Item 7.01. Regulation FD Disclosure.
On November 16, 2022, NanoVibronix, Inc. (the “Company”) issued a press release
announcing the interim results of its clinical study for UroShield. A copy of
the press release is furnished as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated herein by reference. The Company undertakes no
obligation to update, supplement or amend the materials attached hereto.
The information in this Current Report on Form 8-K (including Exhibit 99.1
attached hereto) is being furnished pursuant to Item 7.01 and shall not be
deemed to be filed for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise be subject to the
liabilities of that section, nor shall it be deemed to be incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, whether made before or after the date hereof and regardless of any
general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit Number Description 99.1 Press Release dated November 16, 2022 (furnished pursuant to Item 7.01) 104 Cover Page Interactive Data File (formatted as Inline XBRL)
© Edgar Online, source Glimpses